The 340B Drug Pricing Program was created with a clear goal: to allow hospitals to provide disadvantaged patients with health care.
In recent years, however, the program’s rapid growth has prompted questions about whether 340B benefits patients. That growth, coupled with a lack of charity care reporting and disclosure, has invited scrutiny of the program.
